- Home
- MDIA vs ACRV Comparison
MDIA vs ACRV Comparison
Compare MDIA & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MDIA | ACRV |
|---|---|---|
| Founded | 2019 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.3M | 82.7M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | MDIA | ACRV |
|---|---|---|
| Price | $0.63 | $2.34 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.67 |
| AVG Volume (30 Days) | 37.9K | ★ 464.7K |
| Earning Date | 11-19-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $127,477,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $805.20 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 83.96 | N/A |
| 52 Week Low | $0.64 | $1.05 |
| 52 Week High | $1.60 | $8.00 |
Technical Indicators
Market Signals| Indicator | MDIA | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 23.55 | 49.82 |
| Support Level | $0.66 | $2.12 |
| Resistance Level | $0.71 | $2.62 |
| Average True Range (ATR) | 0.06 | 0.21 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 4.98 | 32.79 |
Price Performance
Historical ComparisonAbout MDIA Mediaco Holding Inc.
MediaCo Holding Inc is a radio broadcasting media company operating in radio and digital advertising, premium programming, and events. It has two radio stations, WQHT-FM and WBLS-FM, which serve the New York City metropolitan area. The company generates revenue from radio and outdoor advertising sales, events including sponsorships and ticket sales, licensing, and syndication. The company has two business segments: the Audio segment and the Video segment. The company generates the majority of its revenue from the Audio segment.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.